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Abstract
Background: Human Papilloma virus (HPV) is recognized as the etiological agent of benign and malignant ano-genital
lesions. The most prevalent genotypes associated with cervical carcinoma are HPV-16 and -18 worldwide. However, recent
studies have emphasized the role of other genotypes, such as HPV-51, in the pathogenesis of cervical dysplasia. The aim of
the study was to estimate the burden of HPV-51 infection in invasive cervical malignant lesions in Northern Sardinia, Italy.
Methods/Principal Findings: An observational, retrospective, prevalence, mono-center study was carried out to evaluate
the presence of HPV genotypes in tissues biopsies of cervical lesions (CIN-1, CIN-2, CIN-3 and invasive carcinoma) gathered
from 1996 to 2009. Biological samples were collected from women admitted consecutively to a tertiary university hospital
situated in Sassari, Italy. Molecular methods were used to identify 28 oncogenic HPV types. A total of 155 formalin-fixed and
paraffin-embedded cervical tissue samples were analyzed. Approximately half of the cervical lesions were classified as
invasive carcinoma. HPV-DNA was detected in 71% of the samples, with a higher frequency (100%) in those categorized as
invasive neoplasia. Mono- or co-infections were demonstrated in 45.8% and 25.8% of the cervical samples, respectively.
Overall, the most prevalent HPV types were -16 (49%) and -51 (19.4%), with an increased frequency of detection associated
with the severity of the cervical lesions.
Conclusions/Significance: This survey highlights for the first time the relevant role of HPV-51 infection in the pathogenesis
of invasive cervical cancer prior to the introduction of a vaccination program. Although a selection bias could have
influenced the results, other recent studies have described the impact of HPV-51. This remarkable epidemiological element
should be carefully evaluated, particularly in the view of opting for preventive vaccines, whose cross-protection patterns
determine their efficacy in protecting against infection from HPV types that are not included in the vaccine itself.
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Introduction
Cervical cancer is deemed the third most frequent neoplasia in
women worldwide; in particular, it is the second most prevalent
cancer among women aged 15–44 years. Recently, it was
estimated an annual number of 529,828 new cases of cervical
carcinoma and of 275,128 deaths from cervical carcinoma [1].
Human Papilloma viruses (HPVs) have been shown to be
associated with cervical cancers since 1976 [2], as a consequence
of a persistent infection which occurs in less than 10% of the
infected women [3]. The majority of sexually active people
(,75%) is infected by HPV types at some point during their
lifetime course [4], [5]. The overall estimated female prevalence of
HPV infection is 11.4% [1]. More than 70% of global cervical
neoplasias have been described to be associated with HPV
genotypes -16 and -18 [1].
On this basis, two prophylactic vaccines containing type -16 and
-18 specific antigens were recently developed; to date, they have
showed a 7–9 year clinical efficacy of about 100% against cervical
cytological abnormalities caused by HPV-16 and -18 genotypes,
with a variable cross-protective efficacy against cervical lesions
associated with other high-risk oncogenic types [6], [7].
A prevalence study showed that other high-risk HPV genotypes
than -16 and -18 (i.e., HPV types -45, -33, -31, -52, -35, -39, -58, -
51, -59, -56, and -66) were associated with more than 20% of
cervical carcinomas globally [8], [9].
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The epidemiology of circulating HPV genotypes was proved to
be heterogeneous and the impact of the vaccines could vary
depending on the regional distribution of HPV types [8].
Recently, our group performed a cross-sectional investigation,
which described a high overall prevalence of HPV genotype -16
(20.5%) and -51 (14.3%) in Northern Sardinia, Italy. Their
presence, as single or coinfecting agents, was detected in all kind of
cytological lesions; in particular, HPV types -16 and -51 DNA
were detected in 12.5 and 6.3% of atypical sqamous cells of
undetermined significance; 24.0% and 16.0% of low-grade
squamous intraepithelial lesions; 50.0% and 50.0% of high-grade
squamous intraepithelial lesions, respectively [8]. A similar
epidemiological pattern was also described by other previous
studies [11], [12], [13], [14].
Since an unexpected proportion of some genotypes could be
due to random variability in limited geographical areas, in order to
evaluate the epidemiological dynamics of HPV-51, particularly in
invasive cervical lesions, we investigated the presence of HPV
DNA in embedded tissues samples of cervical lesions collected in




Ethical approval and informed consent for this study was
unnecessary, according to the Italian legislation concerning the
guidelines for the performance of observational studies (G.U.
n. 76. 31-3-2008). However, a formal approval of the study
protocol was requested in 2007 to the Ethical Committee of the
Azienda Sanitaria Locale nu1 of Sassari, Italy (PN-132, 2007).
Design of the Study
An observational, retrospective, cross-sectional, mono-center
study was performed in Northern Sardinia, Italy, to evaluate the
prevalence of HPV infection in a subset of embedded cervical
lesions (Cervical Intra-epithelial Neoplasia – CIN-1, 2, 3, and
invasive carcinoma), consecutively collected from 1996 to 2009
and belonging to women admitted to a tertiary university hospital
located in Sassari, Italy.
An ad-hoc case report form was created to record hysto-
pathological and virological information. Data were anonymized
in compliance with the Law Decree No. 196/2003, article 24
(Code for the protection of personal data).
Sample Collection and Virological Analysis
HPV-51 infection was expected to account for 1% of invasive
cervical cancers, on the basis of the estimates of a recent
international prevalence study [8]. Considering the high preva-
lence detected in our previous study (i.e., 50% in high-grade
squamous intraepithelial lesions), an estimated number of three
invasive carcinomas per year was needed to obtain a statistically
significant difference. Therefore, a sample of 69 formalin-fixed
and paraffin-embedded tissues from invasive cervical carcinoma
biopsies, collected from 1996 to 2009, was selected. Concomi-
tantly, it was decided to confirm results obtained in our previous
prevalence study [10] by including tissue-embedded samples from
cervical lesions other than invasive neoplasias (,30 samples for
each grade of cervical histological lesion: CIN-1, CIN-2 and CIN-
3), as well as to exclude possible selection bias between populations
with and without invasive carcinoma.
DNA was isolated after extraction and purification using the
DNeasy kit (Qiagen, Valencia, CA) [15]. Every section was heated
for 20 minutes at 120uC in 180 ml ATL lysis buffer and, then,
incubated at 65uC with Proteinase K overnight. DNA was eluted
in 100 mL and analyzed instantaneously or after a variable storage
at 220uC. [15].
DNA was tested using INNO-LiPA HPV Genotyping Extra,
specific for 28 HPV genotypes (-6, -11, -16, -18, -26, -31, -33, -35,
-39, -40, -43, -44, -45, -51, -52, -53, -54, -56, -58, -59, -66, -68, -
69, -70, -71, -73, -74, -82) [10].
When positivity for HR genotypes -16, -18, -31, -45, -51, and -
52 was found, confirmation was obtained testing samples with an
"in-house" Real-Time quantitative TaqMan PCR assay [10], [16].
Cross-protection against cervical carcinoma from preventive
vaccines was estimated using statistically significant findings
showed in the studies PATRICIA and FUTURE II for the
bivalent and tetravalent vaccines, respectively [17], [18].
Statistical Analysis
Qualitative variables were summarized with percentages and
statistically compared using the z-proportion hypothesis test.
Linear trend for proportions was adopted to test the pattern of
HPV genotypes in different cervical lesions. 95% confidence
intervals were calculated to estimate HPV genotype prevalence.
Logistic regression analysis was performed to assess the role of
potential variables, including infections by several HPV genotypes,
in the development of invasive cervical carcinoma.
A p-value ,0.05 was considered statistically significant.
All the analyses were carried out using the statistical software
Stata 11.0 (StataCorp LP, College Station, Texas).
Results
Cervical tissue samples, obtained during the time period 1996–
2009, from 155 women, whose mean (standard deviation) age was
43.71 (14.68) years, were included in the study.
The majority of the women were affected by invasive carcinoma
(69, 44.5%), followed by CIN-1 (30, 19.4%), CIN-2 (29, 18.7%),
and CIN-3 (27, 17.4%).
A total of 110 out of 155 (71%) embedded-tissues were found to
be positive for HPV-DNA, ranging from 6 (20%) in CIN-1 to 69
(100%) in invasive cervical neoplasia (p-value for linear trend
,0.001) (Table 1).
High-risk genotypes were detected in all HPV-DNA positive
samples (110, 100%), whereas low-risk genotypes were detected in
only 9 cases (9, 5.8%). A higher percentage of tissue positivity for
high-risk HPV oncogenic types was demonstrated in CIN-3 lesions
and invasive neoplasias (92.6% and 100%, respectively).
The prevalence of HPV infection significantly increased
alongside with the age: 25% (2/8) in those aged 15–24 years,
52.5% (21/40) in those aged 25–34 years, 68.3% (28/41) in those
aged 35–44 years, 82.9% (29/35) in those aged 45–54 years,
93.3% (14/15) in those aged 55–64 years, 100.0% (10/10) in those
aged 65–74 years, 100.0% (6/6) in those aged over 75 years (slope
0.13; p-value for linear trend ,0.0001). An indistinguishable
proportional linear trend was observed for the prevalent high-risk
genotypes.
Infection by a single HPV genotype was described in about half
of the samples (71, 45.8%); co-infection with multiple high-risk
and/or low-risk genotypes was found in 40 (25.8%) of cervical
samples, with an increasing linear trend associated with the
severity of the histo-pathological pattern (p-value for linear trend
,0.001).
The most prevalent genotypes were HPV-16 (76, 49.0%) and
HPV-51 (30, 19.4%), which accounted for 64.6% of all detected
genotypes. HPV-16 and/or -51 infection was proved in 75.5%
(83/110) of all HPV-DNA positive samples. The positivity
HPV-51 in Invasive Cervical Cancers
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significantly increased alongside with the severity of the cervical
lesions for the genotypes HPV-16 and -51 (p-value for linear trend
,0.001). Other relevant HPV genotypes were: 45 (52, 5.8%), 31
(7, 4.5%), 69 (7, 4.5%), 71 (7, 4.5%), and 18 (6, 3.9%). The
observed prevalence of HPV-16/51 co-infection (23/155, 14.8%)
was almost similar to that estimated on the basis of single HPV-16
and HPV-51 infections (14.7%; p-value .0.05). Only a few
patients were co-infected by HPV genotypes -16/18 (4, 2.6%).
Among 71 patients infected by a single genotype, the most
frequent were: HPV-16 (41, 57.8%), -51 (5, 7.0%), -31 (4, 5.6%), -
45 (4, 5.6%), and -18 (2, 2.8%).
Cervical carcinomas were positive for HPV-16 and -51 in
76.8% and 36.2%, respectively; the proportion of co-infected cases
was 20.9%. Therefore, the percentage of cervical carcinomas with
at least HPV-16 and/or 51 infection was 81.2% (56/69). The
estimated proportion of cases potentially protected by the current
vaccines (i.e., HPV-16, -18, -31, -33, -45, and -51) is 92.8%.
In particular, cross-protection against HPV-16 and -18 nearest
genotypes (i.e., HPV-31, -33, -45, -51), conferred by the current
preventive bivalent and tetravalent vaccines, could be 11.4% and
1.5%, respectively, based on cross-protective efficacy data [17],
[18].
A stepwise logistic regression analysis was carried out in order to
assess the potential covariates associated with the occurrence of
invasive cervical carcinoma (Table 2). The univariate analysis
showed a statistically significant role of the HPV genotypes -16
(OR: 9.07; p-value ,0.0001), -51 (OR: 9.20; p-value ,0.0001),
and -45 (OR: 11.14; p-value: 0.025); the adjusted analysis
confirmed the significant association for the HPV genotypes -16
(OR: 19.82; p-value ,0.0001), -51 (OR: 11.32; p-value: 0.004),
and -45 (OR: 22.07; p-value: 0.033).
The proportional distribution of the main HPV genotypes (i.e., -
16, -51, and -45) responsible of invasive cervical carcinoma did not
significantly change during the study period (p-values for linear
trend .0.05); however, the analysis of the temporal trend of the
only HPV-51 genotype prevalence, in mono- or co-infection,
significantly changed due to non-random variability (chi-square
for trend of proportions; p-value ,0.0002) (Figure 1). The
retrospective nature of the study did not allow further analyses
to assess the role of covariates in the proportional variability of the
main genotypes.
Discussion
The present study confirms the primary role of HPV-16 in the
pathogenesis of cervical carcinoma and describes an unusual high
prevalence of HPV-51 infection (36.2%) in embedded invasive
cervical neoplasias in Northern Sardinia, Italy, in a pre-
vaccination period (1996–2007). It confirms that HPV-51, rarely
detected in other geographical areas [8], [19], is a frequent cause
of cervical lesions in Northern Sardinia, as previously showed [10].
Furthermore, the present survey indicates that HPV-51 prevalence
increases alongside with the cervical lesion severity (from 0% in
CIN-1 lesions to 36.2% in invasive carcinomas; p-value ,0.05) as
well as increasing age significantly correlates with lesion severity,
explaining the increased HPV-51 prevalence trend alongside with
increasing age in our setting.
To our knowledge, this is the first study pointing out such a
strong association between HPV-51 and invasive cervical cancer
(OR 9.2; IC95%: 3.3–25.7).
As previously discussed [10], three major hypotheses could be
provided to clarify the estimated relevant epidemiological impact
of HPV-51 in our territory: a) a possible selection bias due to a
voluntary based PAP test screening instead of a systematic one,
that might have enrolled patients with an higher prevalence of
symptoms; b) a random temporal variability in this restricted
geographical area; c) a true higher prevalence of HPV-51 infection
and/or, conversely, an under-reporting of its prevalence in other
areas.
With regards to a potential selection bias, it was already showed
that, even if this possibility cannot be excluded, it may not play a
role, as no significant differences were detected between HPV
positive and negative women in terms of PAP test compliance in
the years preceding our survey [10].
On the other hand, if the high prevalence demonstrated for
HPV-51 is due to a random variability in this restricted geographic
area, it should have been lower in the past, in particular in cervical
neoplasias occurring several decades after the HPV infection.
Therefore, the high prevalence of HPV-51 in embedded tissues
from invasive cervical carcinomas, with a significant temporal
differences since 1996 up to recent years, strongly indicates that
this HPV genotype has been endemic in Northern Sardinia at least
for the last thirty years.
On this basis, the high HPV-51 prevalence could be deemed a
peculiar epidemiological feature of Northern Sardinia. However,
the higher diagnostic accuracy of the molecular methods
implemented in our study might have positively affected the
sensitivity of the survey, explaining, consequently, the differences
found comparing our findings with the results of other studies,
which used different diagnostic techniques [19]. Recent epidemi-
ological studies showing high HPV-51 frequency in several
geographical areas could support the hypothesis of previous
underreporting for some HPV types owing to less sensitive tools
[20], [21], [22], [23], [24], [25], even if HPV-51 is frequently
detected in co-infection with other types mainly in developing
countries, characterized by a higher HPV genotype variability and
HIV-infection [26], [27], [28], [29], [30]. Based on this
assumption, the epidemiological differences identified in several
areas might be reduced in the near future scaling-up new sensitive
methods.
Results from this epidemiological study indirectly indicate that
current vaccines may prevent infection by HPV genotypes
circulating in Northern Sardinia, particularly as a result of the
use of the bivalent vaccine owing to its larger cross-protective
effect against HPV genotypes, including HPV-51. Current
available vaccines are in fact believed to prevent more than 70%
Table 2. Logistic regression analysis of the covariates
associated with the invasive cervical carcinoma.
HPV genotype Univariate analysis Adjusted* analysis
OR p-value (95% CIs) OR p-value (95% CIs)
HPV-16 9.07 ,0.0001 (4.34–18.92) 19.82 ,0.0001 (5.55–
70.82)
HPV-18 1.26 0.78 (0.25–6.44) – –
HPV-33 1.91 0.49 (0.31–11.76) – –
HPV-45 11.14 0.025 (1.35–91.4) 22.07 0.033 (1.29–
378.83)
HPV-51 9.20 ,0.0001 (3.29–25.72) 11.32 0.004 (2.13–60.17)
Increasing age,
years
1.16 ,0.0001 (1.11–1.22) 1.19 ,0.0001 (1.12–
1.27)
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of the cases of cervical carcinoma owing to their cross-protection
activity. Nevertheless, it is presently unclear if data on cross-
protective efficacy, obtained from clinical trials, indicates long-
lasting immunity [31]. Clinical trials on HPV vaccines were
primarily designed to test the efficacy of immunization against
HPV genotypes -16 and -18. The evaluation of cross-protection
was only a secondary objective; consequently, the sample size was
computed to statistically evaluate the primary objective. However,
it is relevant to highlight the overall elevated efficacy of HPV
vaccines against CIN2 and CIN3 lesions, irrespective of HPV
genotypes.
However, the introduction of HPV vaccines in the Italian
market, followed by the implementation of a specific public health
program, could modify the epidemiological scenario, favoring the
spread of HPV genotypes whose antigens are not included in the
vaccines. This has been described for other bacterial infections
following the introduction of vaccination programmes [32], even if
the replacement phenomenon sporadically described for HPV
[33] is considered to have a very low probability of occurrence
[34].
Data obtained from this prevalence survey will allow to evaluate
the possible epidemiological impact of HPV vaccine on the
etiological dynamics of cervical cancer; in particular, to determine
whether the implementation of a vaccination program based on
the bivalent (HPV-16, HPV-18) vaccine in Northern Sardinia can
reduce the burden of HPV-51 infection as a consequence of its
cross protective efficacy against HPV-31, -33, -45, and -51 [7].
Several limitations can be indentified in the survey carried out
in Northern Sardinia: firstly, the cross-sectional nature of this
study could not permit to adequately evaluate the dynamics of the
HPV genotypes circulation in North Sardinia, being an observa-
tional, prospective design more suitable to recognize temporal
changes. Nevertheless, the 10-year period selected for this study is
deemed to be sufficient to give an overview of the HPV genotype
prevalence in the pre-vaccination era, when, theoretically, no
selective pressure for ecological changes occurred in this
geographical area.
The confidence intervals of the estimates of the prevalence data
show a wide range for some of the less frequent HPV genotypes,
underlying an issue of poor statistical power; therefore, an under-
reporting of cervical lesions, particularly CIN lesions, could be
hypothesized, although samples of all invasive cervical carcinomas,
notified in the study period to the official Northern Sardinian
registry, were collected to undergo molecular analysis for HPV-
DNA. Moreover, we consecutively enrolled samples of individuals
complaining of clinical symptoms and, consequently, a selection
bias could not be excluded, though our previous prevalence study
[10] did not identify any statistical difference between women with
and without symptoms in terms of compliance to PAP smear
testing.
In conclusion, as previously reported, this study has confirmed
the high prevalence of HPV infection in women with cervical
dysplasia and invasive disease in our region; moreover, it
highlighted the role of HPV-51 in determining invasive disease,
emphasizing the importance of orienting immunoprophylaxis
towards this HPV type in the prevention of cervical cancer in our
geographical area.
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